Zonisamide is an fDA-approved antiepileptic compound that blocks voltage-dependent sodium (+) and T-type calcium channels.
Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.
Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.
Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.
Zotatifin is a first-in-class, sequentially selective inhibitor of RNA helicase eIF4A1.
Zotepine is a potent 5-HT2A, 5-HT2C, histamine H1, α1-adrenergic, and dopamine D2 receptor antagonist with Kd values of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively.
Zotepine is a potent 5-HT2A, 5-HT2C, histamine H1, α1-adrenergic, and dopamine D2 receptor antagonist with Kd values of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively.
Zotepine is a potent 5-HT2A, 5-HT2C, histamine H1, α1-adrenergic, and dopamine D2 receptor antagonist with Kd values of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively.
Zotepine is a potent 5-HT2A, 5-HT2C, histamine H1, α1-adrenergic, and dopamine D2 receptor antagonist with Kd values of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively.
Zotiraciclib (TG02, SB1317) is an orally bioavailable, brain penetrant multi-kinase inhibitor of CDK2, JAK2, and FLT3 with IC50 values of 13, 73, and 56 nM, respectively.
Zotiraciclib (TG02, SB1317) is an orally bioavailable, brain penetrant multi-kinase inhibitor of CDK2, JAK2, and FLT3 with IC50 values of 13, 73, and 56 nM, respectively.
Zotiraciclib (TG02, SB1317) is an orally bioavailable, brain penetrant multi-kinase inhibitor of CDK2, JAK2, and FLT3 with IC50 values of 13, 73, and 56 nM, respectively.